Inducing Dry Eye Disease Model
Corresponding Organization :
Other organizations : Lille Inflammation Research International Center
Variable analysis
- Topical application of 5 μL of 0.2% BAK (B6295; Sigma Aldrich, France) or PBS as a control twice a day for 10 days
- Topical administration of IL13 (5 ng of rIL13 (5 μL; SRP4166; Sigma Aldrich, France)) twice a day for four days
- Decrease of CGC, a component of disease mechanism that leads to dry eye
- CGC differentiation
- Topical application of PBS as a control for BAK treatment
- Positive control: Topical application of 0.2% BAK
- Negative control: Topical application of PBS
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!